HC Wainwright Analysts Lift Earnings Estimates for ProKidney

ProKidney Corp. (NASDAQ:PROK) – Research analysts at HC Wainwright raised their Q2 2026 earnings estimates for ProKidney in a research note issued to investors on Monday, May 18th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.11) for the quarter, up from their prior forecast of ($0.13). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for ProKidney’s current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for ProKidney’s Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($0.54) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at ($0.37) EPS.

ProKidney (NASDAQ:PROK) last issued its earnings results on Friday, May 15th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.10 million.

A number of other brokerages have also weighed in on PROK. Wall Street Zen lowered shares of ProKidney from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProKidney in a research report on Tuesday, April 21st. Finally, Jefferies Financial Group upgraded shares of ProKidney to a “strong-buy” rating in a research report on Wednesday, March 18th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.40.

ProKidney Stock Down 3.7%

Shares of NASDAQ:PROK opened at $1.55 on Wednesday. The firm has a market capitalization of $467.98 million, a PE ratio of -2.92 and a beta of 1.70. ProKidney has a twelve month low of $0.54 and a twelve month high of $7.13. The company has a 50-day moving average price of $1.93 and a two-hundred day moving average price of $2.16.

Hedge Funds Weigh In On ProKidney

A number of large investors have recently modified their holdings of the company. Bank of America Corp DE boosted its position in shares of ProKidney by 6.7% in the first quarter. Bank of America Corp DE now owns 753,412 shares of the company’s stock valued at $1,349,000 after acquiring an additional 47,268 shares during the period. Amundi boosted its position in shares of ProKidney by 7.2% in the first quarter. Amundi now owns 291,708 shares of the company’s stock valued at $522,000 after acquiring an additional 19,466 shares during the period. SummitTX Capital L.P. bought a new position in shares of ProKidney in the first quarter valued at approximately $26,000. Renaissance Technologies LLC boosted its position in shares of ProKidney by 39.6% in the first quarter. Renaissance Technologies LLC now owns 1,250,794 shares of the company’s stock valued at $2,239,000 after acquiring an additional 355,089 shares during the period. Finally, R Squared Ltd bought a new position in shares of ProKidney in the first quarter valued at approximately $25,000. 51.59% of the stock is currently owned by institutional investors.

Key ProKidney News

Here are the key news stories impacting ProKidney this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating on ProKidney and kept a $12.00 price target, implying significant upside from current levels. The firm also raised near-term earnings estimates for Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, and FY2028, which suggests improving expectations for the company’s loss profile.
• Neutral Sentiment: HC Wainwright’s estimate changes were mixed across the out years, with FY2030 lowered while earlier periods were revised higher. That makes the overall message positive on the nearer-term outlook but less uniformly bullish long term. FY2030 EPS Estimates for ProKidney Lowered by HC Wainwright
• Neutral Sentiment: Recent commentary from the analyst also appears to have repeated the same core view: a Buy rating with a high price target, but the company is still expected to remain unprofitable in the near term.
• Negative Sentiment: Even with the analyst support, ProKidney remains a pre-profit biotech story, and the stock may be under pressure because investors are still focused on losses and execution risk rather than current earnings strength.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.